Brent Zettl resigns as CEO of CanniMed

Brent Zettl has resigned from his position as CEO of CanniMed, effective immediately, to pursue other opportunities. Mr. Zettl has agreed to remain available to CanniMed and Aurora in an advisory capacity to assist during the integration period.

"On behalf of the CanniMed board, I would like to express our gratitude to Brent for his leadership of CanniMed over the past three decades," stated John Knowles, CFO and Director of CanniMed. "CanniMed is the pioneer in the Canadian medical cannabis industry and this is in no small part thanks to Brent and the huge contributions he has made to the development of the sector. We wish Brent well with his future ventures."

Mr. André Jérôme was appointed as Interim CEO. Mr. Jérôme is SVP Business Integration at Aurora, where he is responsible for the integration of acquisitions, as well as for the identification of potential synergies across existing subsidiaries and joint venture partners. Mr. Jérôme, a member of the Bar of Québec for the last 23 years, joined Aurora from H2 Biopharma Inc ("H2"), where he was CEO and co-founder. Mr. Jérôme was already tasked with heading up the integration of CanniMed into the Aurora organization.

Mr. Terry Booth, Aurora CEO, added, "André is the right person to take on the role of Interim CEO at CanniMed. He is a consummate business professional and team leader with an excellent track record in accelerating growth. We are also very pleased that Brent has agreed to remain available to us as an advisor, which will provide additional support to ensure the transition proceeds smoothly. The integration of Aurora and CanniMed is well underway, and we anticipate updating the market frequently on developments as CanniMed is aligned with the Aurora Standard and expands its footprint in the domestic and international medical cannabis sectors."

For more information:
Aurora
P.O. Box 209
Cremona, AB. T0M0R0
1-844-928-7672
auroramj.com